ArticleJournal of clinical medicine2022
Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05997433 (Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori), which is not on this map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori : A Multicenter Randomized Non-Inferiority Trial
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.
- [Evidence-Based Guidelines for the Diagnosis and Treatment ofThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026Guideline
- Guideline
- Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-ResistantGut and liver · 2024Trial
- Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- Practical Efficacy of a 1-Week Metronidazole-Based Triple Regimen Plus Bismuth Versus a 2-Week Bismuth-Based Quadruple Regimen for Helicobacter pylori Infection With Clarithromycin-Resistance-Associated Genetic Mutations.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- Potential Unnecessity of Bismuth in Standard Triple Therapy for Clarithromycin-Susceptible Helicobacter pylori Infection.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- Efficacy and Safety of 10-Day Versus 14-Day Bismuth-Containing Quadruple Therapy forJGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Can Patients with Clarithromycin-ResistantGut and liver · 2024Article
- [Eradication ofThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsPoint mutations in the 23S ribosomal RNA gene have been associated with
methodsWe retrospectively investigated treatment-naïve
resultsTotal eradication extent of
conclusionsThe 7-day BQT regimen was as effective as the 14-day BQT regimen in the eradication of treatment-naïve clarithromycin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.